Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Has announcements × von Hippel-Lindau Disease × belzutifan × Clear all

Phase

Status

Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

von Hippel-Lindau Disease 2 Pheochromocytoma 1 Paraganglioma 1 Kidney Neoplasms 1 Carcinoma, Renal Cell 1 Adenoma, Islet Cell 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04924075 2026-02-24

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03401788 2024-12-03

MK-6482-004

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting

50 enrolled 1 FDA

von Hippel-Lindau Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡